Summary Drug resistance in haemopoietic cells may be partly related to the expression of the glutathione-stransferase (GST) pi and mdr-l genes. We have used RNA slot blotting techniques to investigate the expression of GST pi in peripheral blood and bone marrow of eleven normal subjects, nine patients with myelodysplastic syndrome (MDS), eighteen patients with acute myeloblastic leukaemia (AML), and thirty-two patients with chronic lymphocyte leukaemia (CLL). We found increased expression of GST pi in 8 of 9 MDS, (7 peripheral blood, I bone marrow) 12 
Resistance to cytotoxic drugs, either at presentation, or, more frequently, at relapse, is commonly encountered during the treatment of leukaemia. It is well established in vitro that cellular acquisition of the multidrug resistant (MDR) phenotype confers loss of sensitivity to a wide range of structurally unrelated toxins (Biedler & Riehm, 1970; Kartner et al., 1985) . Several distinct drug resistance processes are now recognised which may be involved in clinically resistant leukaemia (Holmes, 1990b) . The mdr-I gene encodes the transmembranous P-glycoprotein (PGP, Mr = 170,000) which acts as an energy-dependent efflux pump and is associated with decreased intracellular accumulation of drugs (Chen et al., 1986; Juliano & Ling, 1976) . The function of the protein encoded by the mdr 2 gene in man is unknown. Mdr-1 gene amplification and increased expression have been seen in the drug-resistant CEM/VLB/100 leukaemia cell line when compared to the parental sensitive CCRF-CEM line. However, mdr 1 gene amplification has not been observed in AML or MDS (Holmes et al., 1989) . Elevated mdr 1 mRNA levels have been reported in many forms of leukaemia (Goldstein et al., 1989; Holmes et al., 1989 Holmes et al., , 1990a .
The glutathione-s-transferases (GST) have also been implicated in drug resistance (Hayes & Wolf, 1988) . They comprise four gene families which map to distinct chromosomal locations. Three of these gene families encode cytosolic proteins which have been classified as alpha, mu, and pi (Mannervik et al., 1985) . GST isozymes catalyse the conjugation of electrophilic drugs, toxins and carcinogens to reduced glutathione which leads to detoxification. They also detoxify organic hydroperoxides and bind and sequester other foreign compounds (Ketterer et al., 1986) . Increased expression of a variety of GST subunits has been observed in cell lines made resistant to cytoxic drugs. (Hayes & Wolf 1988) . In certain cases concomitant over expression of both GST pi and mdr-1 mRNA have been observed (Cowan et al., 1986) . Over expression of both mdr-l and GST has also been seen in carcinogen-induced preneoplastic lesions in rat liver indicating that there may be co-ordinate expression of these proteins (Kitahara et al., 1984) . Elevated levels of GST pi, mRNA have been found in a variety of haematological malignancies but no clear relationship with chemotherapy can be determined. (McQuaid et al., 1989; Moscow et al., 1989 To identify the incidence and possible association of GST pi and mdr-1 expression in leukaemia patients and to study any treatment related changes in the expression of these genes, we have investigated their expression in haemopoietic cells of normal control subjects and untreated and treated patients with MDS, AML and CLL.
Materials and methods
Methods for mdr-1 expression have previously been published (Holmes et al., 1989 (Holmes et al., , 1990a DNA and total RNA were extracted by lysis in guanidine thiocyanate and centrifugation in a caesium chloride gradient (Maniatis et al., 1982) . Concentrations of mRNA were determined spectrophotometrically and duplicate slot blots were made with five doubling dilutions of total mRNA (10 gg to 0.625 tg) on to Hybond N (Amersham) membranes. Each slot blot included the CEM line and its drug-resistant derivative CEM/VLB/100 as negative and positive controls respectively for mdr expression (Beck et al., 1979) . Hybridisation was carried out using a 414 bp fragment of the mdr cDNA P5L-18 (Scotto et al., 1986) as described by Holmes et al. (1989) and then to a full length GST pi cDNA (Kano et al., 1987) . Probes were labelled with 32PdCTP by primer extension (Boehringer). Quantitation of RNA was carried out by hybridisation with a human B-actin (PHA4.1) probe (Khalili et al., 1983) . The blots were finally washed with 2 x SSC, (sodium chloride, sodium citrate), 1% SDS (sodium dodecyl sulphate), at 65°C for 1 hour, and 0.1 x SSC 1% SDS at 60°C for 30 minutes for GST pi and B actin respectively. Kodak XAR-5 film exposed at -70°C for 1-5 days was used for autoradiography. Relative levels of GST pi expression were determined by densitometry.
Results
Results are summarised in Table I . The data relating to mdr-1 expression in the same samples examined here have been published previously (Holmes et al., 1989 (Holmes et al., , 1990a .
Representative data for relative levels of GST pi expression in a normal control, CEM and CEM/VLB/100 cell line and patients with increased expression in MDS, AML and CLL are shown in Figure 1 . Total peripheral leucocytes from the same 10 normal controls and total bone marrow from one individual demonstrated a range of GST pi mRNA expression of 1 to 3 arbitrary units. It was hoped that analysis of GST pi expression in normal myeloid and lymphoid fractions in peripheral blood could be obtained as had been completed with mdr analysis. However, no signal could be detected from the relevant membranes and no RNA was available to construct further blots. All peripheral blood samples contained 30-40% lymphocytes whilst the one bone marrow examined held less than 5% lymphocytes. It is not feasible to obtain data on GST pi expression on normal blast cells since approximately 108 cells are required for RNA extraction. Therefore, no truly adequate control exists for the analysis of GST pi expression in AML. We have compared GST pi RNA level in CLL to those in total peripheral blood. Ideally data on normal lymphoid fractions would have provided better controls.
All pre-leukaemic and leukaemic samples contained GST pi mRNA within a 28-fold range of variations in expression. Eight of nine (one bone marrow, seven total peripheral blood) patients with MDS of all sub-types demonstrated the breast, 6 units), and 7 of 11 cases of relapsed or refractory AML (4-24 units). Repeated measurements on three patients with GST pi levels (6, 8, 13 units) at presentation had the same or decreased expression after chemotherapy (2, 3, 6 units). Of the CLL patients 3 of 7 untreated (5-27 units) and 21 of 25 treated (4-28 units) demonstrated increased mRNA in peripheral blood. Sequential measurements on two patients could not demonstrate a change in gene expression with exposure to intermittent chlorambucil. Gene amplification of GST pi could not be demonstrated in any of the patient material screened. Of all patients, those with normal GST pi and mdr-I expression include none with MDS, one case of relapsed secondary AML, two untreated and four treated patients with CLL. Out of a total of 59 patients, only 7 patients had neither gene upregulated. In view of the possible association between GST pi and mdr-l expression, a comparison was made between the relative levels in the same samples. There was no obvious association except for a possible weak correlation between GST pi and mdr-l mRNA levels in CLL (Figure 2 ).
Discussion
As it is likely that malignant cells can use several mechanisms to achieve a drug-resistant state and maintain a proliferative advantage we have investigated the possible associations and relevance of two mechanisms that are currently considered to be important. Moscow et al. (1989) reported over expression of PGP and GST pi in the AdrR MCF-7 breast carcinoma line and rat hyperplastic nodules. They further investigated 23 cases of lymphoma and observed generally higher levels of mdr-l mRNA in low grade compared to high grade tumours whilst GST pi levels were uniformly low. Analysis of 7 cases of pre-B ALL suggested that increased GST pi expression is present before chemotherapy and may be higher at relapse. (Holmes et al., 1990a) .
We have previously demonstrated mdr-l gene amplification and increased RNA expression in the drugresistant CEM/VLB/100 leukaemic line when compared to the parental sensitive CEM line (Holmes et al., 1989) . However, both the sensitive and resistant lines express similar levels of GST pi mRNA compared to normal peripheral blood and bone marrow. This suggests, in agreement with Moscow et al. (1989) , that GST pi upregulation may be an inherent feature of lymphoblastic leukaemia. However, ALL, particularly in children, is chemosensitive raising a question concerning the relevance of increased GST pi expression. These data also suggest that the mdr-l and GST pi gene may act independently to confer drug resistance.
Elevated levels of mdr-l mRNA as compared to the basal expression of the drug sensitive CEM leukaemic cell line are more common in secondary and relapsed/refractory AML than in untreated AML (Holmes et al., 1989) . Repeated measurements in three patients with AML with basal levels of mdr-l mRNA at presentation, that is comparable to the CEM line, have shown that levels can be significantly increased at relapse. In contrast, GST pi levels are more commonly elevated above the normal range for blood and bone marrow in primary than secondary AML and repeated measurements on the same three patients suggest that RNA levels remain the same or fall after chemotherapy. This suggests that, unlike mdr-l, GST (Holmes et al., 1990a) . GST pi upregulation appears more common in treated than untreated CLL although no clear relationship could be demonstrated in two patients treated with chlorambucil. There are now various reports which suggest an association between GST pi and mdr-l expression (Kitahara et at., 1984; Gowan et at., 1986; Burt et al., 1988 Within the AML and CLL groups there were patients, albeit a minority, (7 out of 50) with clinically resistant disease and no apparent involvement of either of these drug resistance mechanisms, which suggests that other processes may be clinically relevant. Potmesil et al. (1988) have demonstrated low levels of topoisomerase II in CLL suggesting this as a clinically relevant route to a drug-resistant state for those tumours with a large population of non-proliferating cells.
Although the clinical relevance of these data is not clear, the relationship of mdr-I and GST pi expression to chemotherapy may provide important considerations for the future design of therapeutic regimes and suggest a complex relationship between drug resistance mechanisms in leukaemia.
